Dr Lee highlights the latest treatment developments in non–clear cell renal cell carcinoma, emphasizes the need for more precise classification of the histologic subsets of this disease, and discusses the investigation of cabozantinib plus nivolumab across stratified cohorts of non–clear cell renal cell carcinoma.
